TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ANIK

Anika Therapeutics Inc

Healthcare · Drug Manufacturers - Specialty & Generic

21.00$ +0.9% vs. previous close Closing price · As of: Sep 17, 2026

Investor relations

Report Dates

Investor relations overview for Anika Therapeutics Inc (ANIK): report dates, earnings surprises, earnings call transcripts and the latest headlines. The next report is scheduled for 11/04/2026.

Next report 11/04/2026
Last report 07/29/2026
Earnings surprise by quarter (%)
Q3 23 · -28.6 % 23 Q4 23 · -1,553.9 % 23 Q1 24 · 80.0 % 24 Q2 24 · -15.0 % 24 Q3 24 · -183.3 % 24 Q4 24 · -27.3 % 24 Q1 25 · -166.7 % 25 Q2 25 · 0.0 % 25 Q3 25 · 10.5 % 25 Q4 25 · 168.4 % 25 Q1 26 · 268.8 % 26 Q2 26 · 257.9 % 26

EPS estimate beaten

Full history 62 of 98 quarters (63%)
Last 16 quarters 7 of 16 quarters (44%)

Earnings Call Transcripts

Search all transcripts →

  • 07/29/2026 Earnings Call Q2 2026 Open →
  • 04/29/2026 Earnings Call Q1 2026 Open →
  • 02/26/2026 Earnings Call Q4 2025 Open →
  • 11/05/2025 Earnings Call Q3 2025 Open →
  • 07/30/2025 Earnings Call Q2 2025 Open →
  • 05/09/2025 Earnings Call Q1 2025 Open →
  • 03/12/2025 Earnings Call Q4 2024 Open →
  • 11/02/2024 Earnings Call Q3 2024 Open →
  • 08/11/2024 Earnings Call Q2 2024 Open →
  • 05/08/2024 Earnings Call Q1 2024 Open →

News on This Stock

  • 07/29/2026 Anika Therapeutics, Inc. (ANIK): Results of Operations and Financial Condition; Financial Statements and Exhibits · sec.gov Open ↗
  • 07/14/2026 Anika Therapeutics, Inc. (ANIK): Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Financial Statements and Exhibits · sec.gov Open ↗

Automatically matched wire and portal stories; external links open the original source.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Transcripts: transcript archive

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?